Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma.

Authors

Krish Patel, Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA, USAFollow
Alexey V Danilov
John M Pagel, Swedish Cancer Institute, Center for Blood Disorders and Stem Cell Transplantation, Seattle, WAFollow

Document Type

Article

Publication Date

11-7-2019

Publication Title

Blood

Keywords

Antineoplastic Agents; Humans; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Purines

Abstract

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma (FL) represent indolent malignancies characterized by multiple episodes of relapse. Therapy has centered on agents that largely target the B-cell receptor pathway. Duvelisib is a second-generation oral inhibitor of phosphoinositide-3 kinase, downstream of the B-cell receptor pathway, approved in the United States for relapsed CLL/SLL and FL. Duvelisib represents a highly active agent, and ongoing investigations, including fixed-duration drug combinations and alternative dosing schedules, are aimed at reducing immune-mediated toxicities.

Clinical Institute

Cancer

Department

Oncology

Department

Hematology

Recommended Citation

Patel, Krish; Danilov, Alexey V; and Pagel, John M, "Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma." (2019). Articles, Abstracts, and Reports. 2852.
https://digitalcommons.providence.org/publications/2852